Cargando…

Long-term use of yeast fermentation products in comparison to halofuginone for the control of cryptosporidiosis in neonatal calves

The objective of this study was to compare the effect of non-GMO Saccharomyces cerevisiae fermentation products (SCFP) with that of a halofuginone treatment against Cryptosporidium parvum infection in pre-weaned calves on a commercial dairy farm. A total of 123 neonatal female calves, housed in indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vélez, Juan, Lange, Malin K., Zieger, Peter, Yoon, Ilkyu, Failing, Klaus, Bauer, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117046/
https://www.ncbi.nlm.nih.gov/pubmed/31079829
http://dx.doi.org/10.1016/j.vetpar.2019.04.008
_version_ 1783514289150099456
author Vélez, Juan
Lange, Malin K.
Zieger, Peter
Yoon, Ilkyu
Failing, Klaus
Bauer, Christian
author_facet Vélez, Juan
Lange, Malin K.
Zieger, Peter
Yoon, Ilkyu
Failing, Klaus
Bauer, Christian
author_sort Vélez, Juan
collection PubMed
description The objective of this study was to compare the effect of non-GMO Saccharomyces cerevisiae fermentation products (SCFP) with that of a halofuginone treatment against Cryptosporidium parvum infection in pre-weaned calves on a commercial dairy farm. A total of 123 neonatal female calves, housed in individual hutches, were enrolled sequentially based on date of birth in 41 blocks of 3 animals each. Calves within each block were allocated to one of 3 treatments: remaining untreated, fed with SCFP (Diamond V SmartCare(®) at 1 g/d in milk and NutriTek(®) at 5 g/d in starter grain) for the first 63 days of life, or treated with halofuginone (0.1 mg/kg/d) for the first 7 days of life. Fecal samples collected on days 4–21 post-partum were examined for both Cryptosporidium oocysts and coproantigen. The presence and intensity of diarrhea were monitored by scoring daily for the first 4 weeks of life. Calves were weighed at 0, 21, 42 and 63 days of age. Almost all calves were Cryptosporidium-positive at least once during the study. Halofuginone significantly reduced the number of Cryptosporidium-positive fecal samples as compared to the two other groups. Based on the coproantigen scores, both halofuginone and SCFP feeding significantly reduced the intensity of Cryptosporidium infection as compared to the untreated group. Diarrhea was recorded in almost all calves at least once. Neither the proportion of diarrheic calves nor the intensity and duration of diarrhea differed among the 3 treatment groups significantly. The mean daily weight gain during the first 3 weeks of life was significantly lower in halofuginone treated calves than in both other groups; however, at the end of the study period the total weight gain did not significantly differ among the 3 treatment groups. In conclusion, the clinical results and weight gains of pre-weaning supplementation with the SCFP were neither better nor worse than the 7-day halofuginone treatment suggesting that the SCFP feeding may be from the clinical point of view a natural alternative measure, instead of halofuginone treatment, in bovine cryptosporidiosis.
format Online
Article
Text
id pubmed-7117046
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71170462020-04-02 Long-term use of yeast fermentation products in comparison to halofuginone for the control of cryptosporidiosis in neonatal calves Vélez, Juan Lange, Malin K. Zieger, Peter Yoon, Ilkyu Failing, Klaus Bauer, Christian Vet Parasitol Article The objective of this study was to compare the effect of non-GMO Saccharomyces cerevisiae fermentation products (SCFP) with that of a halofuginone treatment against Cryptosporidium parvum infection in pre-weaned calves on a commercial dairy farm. A total of 123 neonatal female calves, housed in individual hutches, were enrolled sequentially based on date of birth in 41 blocks of 3 animals each. Calves within each block were allocated to one of 3 treatments: remaining untreated, fed with SCFP (Diamond V SmartCare(®) at 1 g/d in milk and NutriTek(®) at 5 g/d in starter grain) for the first 63 days of life, or treated with halofuginone (0.1 mg/kg/d) for the first 7 days of life. Fecal samples collected on days 4–21 post-partum were examined for both Cryptosporidium oocysts and coproantigen. The presence and intensity of diarrhea were monitored by scoring daily for the first 4 weeks of life. Calves were weighed at 0, 21, 42 and 63 days of age. Almost all calves were Cryptosporidium-positive at least once during the study. Halofuginone significantly reduced the number of Cryptosporidium-positive fecal samples as compared to the two other groups. Based on the coproantigen scores, both halofuginone and SCFP feeding significantly reduced the intensity of Cryptosporidium infection as compared to the untreated group. Diarrhea was recorded in almost all calves at least once. Neither the proportion of diarrheic calves nor the intensity and duration of diarrhea differed among the 3 treatment groups significantly. The mean daily weight gain during the first 3 weeks of life was significantly lower in halofuginone treated calves than in both other groups; however, at the end of the study period the total weight gain did not significantly differ among the 3 treatment groups. In conclusion, the clinical results and weight gains of pre-weaning supplementation with the SCFP were neither better nor worse than the 7-day halofuginone treatment suggesting that the SCFP feeding may be from the clinical point of view a natural alternative measure, instead of halofuginone treatment, in bovine cryptosporidiosis. Published by Elsevier B.V. 2019-05 2019-04-19 /pmc/articles/PMC7117046/ /pubmed/31079829 http://dx.doi.org/10.1016/j.vetpar.2019.04.008 Text en © 2019 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Vélez, Juan
Lange, Malin K.
Zieger, Peter
Yoon, Ilkyu
Failing, Klaus
Bauer, Christian
Long-term use of yeast fermentation products in comparison to halofuginone for the control of cryptosporidiosis in neonatal calves
title Long-term use of yeast fermentation products in comparison to halofuginone for the control of cryptosporidiosis in neonatal calves
title_full Long-term use of yeast fermentation products in comparison to halofuginone for the control of cryptosporidiosis in neonatal calves
title_fullStr Long-term use of yeast fermentation products in comparison to halofuginone for the control of cryptosporidiosis in neonatal calves
title_full_unstemmed Long-term use of yeast fermentation products in comparison to halofuginone for the control of cryptosporidiosis in neonatal calves
title_short Long-term use of yeast fermentation products in comparison to halofuginone for the control of cryptosporidiosis in neonatal calves
title_sort long-term use of yeast fermentation products in comparison to halofuginone for the control of cryptosporidiosis in neonatal calves
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117046/
https://www.ncbi.nlm.nih.gov/pubmed/31079829
http://dx.doi.org/10.1016/j.vetpar.2019.04.008
work_keys_str_mv AT velezjuan longtermuseofyeastfermentationproductsincomparisontohalofuginoneforthecontrolofcryptosporidiosisinneonatalcalves
AT langemalink longtermuseofyeastfermentationproductsincomparisontohalofuginoneforthecontrolofcryptosporidiosisinneonatalcalves
AT ziegerpeter longtermuseofyeastfermentationproductsincomparisontohalofuginoneforthecontrolofcryptosporidiosisinneonatalcalves
AT yoonilkyu longtermuseofyeastfermentationproductsincomparisontohalofuginoneforthecontrolofcryptosporidiosisinneonatalcalves
AT failingklaus longtermuseofyeastfermentationproductsincomparisontohalofuginoneforthecontrolofcryptosporidiosisinneonatalcalves
AT bauerchristian longtermuseofyeastfermentationproductsincomparisontohalofuginoneforthecontrolofcryptosporidiosisinneonatalcalves